# Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer

> **NCT02134990** · PHASE2 · UNKNOWN · sponsor: **Oshadi Drug Administration** · enrollment: 20 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Oshadi D and Oshadi R
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02134990
- **Lead sponsor:** Oshadi Drug Administration
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2019-01
- **Final completion:** 2019-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02134990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02134990, "Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02134990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*